Equities research analysts at HC Wainwright initiated coverage on shares of Climb Bio (NASDAQ:CLYM – Get Free Report) in a note issued to investors on Monday, Marketbeat Ratings reports. The firm set a “buy” rating and a $9.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 378.72% from the company’s previous close.
CLYM has been the subject of a number of other research reports. Robert W. Baird assumed coverage on Climb Bio in a report on Friday, August 15th. They set an “outperform” rating and a $9.00 target price for the company. BTIG Research boosted their price target on Climb Bio from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Tuesday, September 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Climb Bio in a research note on Wednesday, October 8th. Wall Street Zen raised Climb Bio from a “sell” rating to a “hold” rating in a research note on Monday, October 6th. Finally, Baird R W raised Climb Bio to a “strong-buy” rating in a research note on Friday, August 15th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $9.20.
Get Our Latest Research Report on Climb Bio
Climb Bio Stock Performance
Climb Bio (NASDAQ:CLYM – Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.06. On average, equities research analysts predict that Climb Bio will post -1.57 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of CLYM. AQR Capital Management LLC bought a new position in Climb Bio in the first quarter valued at about $27,000. XTX Topco Ltd bought a new position in Climb Bio in the first quarter valued at about $34,000. Qube Research & Technologies Ltd bought a new position in Climb Bio in the second quarter valued at about $43,000. Marshall Wace LLP bought a new position in Climb Bio in the second quarter valued at about $46,000. Finally, Nuveen LLC bought a new position in Climb Bio in the first quarter valued at about $48,000. Institutional investors own 69.76% of the company’s stock.
About Climb Bio
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
Featured Stories
- Five stocks we like better than Climb Bio
- Utilities Stocks Explained – How and Why to Invest in Utilities
- After Gold Blast Soars Past $4,000, BofA Eyes $5,000 in 2026
- How to Short a Stock in 5 Easy Steps
- Buyback Boom: 3 Companies Betting Big on Themselves
- What to Know About Investing in Penny Stocks
- Analysts Flock to Upgrade DELL After Big AI-Server Guidance Boost
Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.